US34986J2042 - ADR
NASDAQ:FWP (8/16/2022, 3:30:01 PM)-0.24 (-6.05%)
|GICS Sector||Health Care|
|Earnings (Last)||04-14 2022-04-14||Earnings (Next)||N/A N/A|
|Ins Owners||N/A||Inst Owners||10.64%|
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
Forward Pharma A/S is a biopharmaceutical company, which engages in the research and development of medicinal treatment for inflammatory and neurological indications. The company is developing a proprietary formulation of dimethyl fumarate (DMF), for the treatment of multiple sclerosis (MS) and other inflammatory and neurological indications. DMF is an immunomodulator that can be used as a therapeutic to improve the health of patients with MS and immune disorders .The Company is headquartered in Copenhagen, Denmark.
FORWARD PHARMA A/S-ADR
Oestergade 24A, 1, Copenhagen K
CEO: Claus Bo Svendsen
COPENHAGEN, Denmark, April 08, 2022 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“we,” “Forward” or the “Company” and, together with its...
Here you can normally see the latest stock twits on FWP, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.